Charles River Laboratories vs Minaris Advanced Therapies: CDMO Comparison
Side-by-side comparison of Charles River Laboratories and Minaris Advanced Therapies on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Charles River Laboratories has more FDA inspections on record (7 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Charles River Laboratories has materially broader EMA GMP coverage (9 active certificates vs 2) — stronger EU footprint.
On a 13-modality CDMO landscape, both Charles River Laboratories and Minaris Advanced Therapies qualify as CAR-T manufacturers; Charles River Laboratories carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both Charles River Laboratories and Minaris Advanced Therapies qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Charles River Laboratories vs Minaris Advanced Therapies
Which has the stronger FDA inspection record, Charles River Laboratories or Minaris Advanced Therapies?
Both Charles River Laboratories and Minaris Advanced Therapies maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Charles River Laboratories has 7 FDA inspections on record; Minaris Advanced Therapies has 1.
How do Charles River Laboratories and Minaris Advanced Therapies compare on European GMP coverage?
Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Minaris Advanced Therapies holds 2 active EMA GMP certificates and 4 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for CAR-T manufacturing — Charles River Laboratories or Minaris Advanced Therapies?
Both Charles River Laboratories and Minaris Advanced Therapies are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Charles River Laboratories carries a Signal Score of 92/100 and Minaris Advanced Therapies carries 84/100 — a small lead for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →